Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $40.62 USD
Change Today -0.49 / -1.19%
Volume 458.0K
PTCT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

ptc therapeutics inc (PTCT) Snapshot

Open
$40.89
Previous Close
$41.11
Day High
$41.33
Day Low
$39.50
52 Week High
04/9/15 - $78.72
52 Week Low
08/24/15 - $29.08
Market Cap
1.4B
Average Volume 10 Days
830.6K
EPS TTM
$-4.08
Shares Outstanding
34.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PTC THERAPEUTICS INC (PTCT)

ptc therapeutics inc (PTCT) Related Bloomberg News

View More Bloomberg News

ptc therapeutics inc (PTCT) Details

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company’s lead product is Translarna (ataluren), which is in Phase III clinical trials for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and for the treatment of cystic fibrosis caused by nonsense mutations. It also intends to develop Translarna for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, as well as develops spinal muscular atrophy, which is in Phase II clinical program. The company’s preclinical development programs include PTC596, a development candidate used for the treatment of chemotherapy resistant cancers; and PTC672, an antibacterial development candidate for the treatment of life-threatening infections caused by multidrug-resistant Gram-negative bacteria. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program. The company was founded in 1998 and is based in South Plainfield, New Jersey.

187 Employees
Last Reported Date: 03/2/15
Founded in 1998

ptc therapeutics inc (PTCT) Top Compensated Officers

Co-Founder, Chief Executive Officer and Execu...
Total Annual Compensation: $495.0K
Chief Commercial Officer
Total Annual Compensation: $368.2K
Chief Medical Officer
Total Annual Compensation: $329.3K
Compensation as of Fiscal Year 2014.

ptc therapeutics inc (PTCT) Key Developments

PTC Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

PTC Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported that total revenues were $6,774,000 compared to $1,677,000 a year ago. Loss from operations was $38,626,000 compared to $25,369,000 a year ago. Net loss was $38,361,000 compared to $25,104,000 a year ago. Net loss per share applicable to common shareholders basic and diluted were $0.86 against $5.51 per share a year ago. For the six months, the company reported that total revenues were $14,256,000 compared to $10,894,000 a year ago. Loss from operations was $76,697,000 compared to $39,581,000 a year ago. Net loss was $76,276,000 compared to $39,202,000 a year ago. Net loss per share applicable to common shareholders basic and diluted were $2.29 against $1.40 per share a year ago.

PTC Therapeutics, Inc. to Report Q2, 2015 Results on Jul 30, 2015

PTC Therapeutics, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Jul 30, 2015

PTC Therapeutics, Inc., Q2 2015 Earnings Call, Jul 30, 2015

PTC Therapeutics, Inc., Q2 2015 Earnings Call, Jul 30, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PTCT:US $40.62 USD -0.49

PTCT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PTCT.
View Industry Companies
 

Industry Analysis

PTCT

Industry Average

Valuation PTCT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 47.7x
Price/Book 5.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 39.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PTC THERAPEUTICS INC, please visit www.ptcbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.